Reformulated Drugs, Real Money: How Pharma Prices Its Way Past Patent Cliffs
Pharma’s “patent cliff” isn’t a cliff anymore. It’s a treadmill.
If you’ve worked anywhere near drug pricing, you’ve seen the pattern: a blockbuster’s exclusivity window starts to narrow, revenue projections get stress-tested, and then—almost like cloc…
Reformulated Drugs, Real Money: How Pharma Prices Its Way Past Patent Cliffs Read Post »
